Thrivent Financial for Lutherans Buys New Shares in Icon Plc $ICLR

Thrivent Financial for Lutherans bought a new stake in shares of Icon Plc (NASDAQ:ICLR) during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund bought 283,502 shares of the medical research company’s stock, valued at approximately $51,660,000.

Other hedge funds and other institutional investors have also bought and sold shares of the company. Muhlenkamp & Co. Inc. bought a new stake in Icon during the 3rd quarter valued at $12,857,000. Mitchell Capital Management Co. bought a new stake in Icon during the 3rd quarter valued at $1,627,000. First National Bank of Omaha bought a new stake in Icon during the 3rd quarter valued at $6,267,000. Allspring Global Investments Holdings LLC increased its stake in Icon by 1.1% during the 4th quarter. Allspring Global Investments Holdings LLC now owns 1,080,192 shares of the medical research company’s stock valued at $203,800,000 after purchasing an additional 11,335 shares in the last quarter. Finally, CIBC Bancorp USA Inc. bought a new stake in Icon during the 3rd quarter valued at $39,074,000. Institutional investors own 95.61% of the company’s stock.

Icon Stock Down 0.6%

ICLR stock opened at $116.38 on Friday. The stock’s fifty day simple moving average is $109.72 and its two-hundred day simple moving average is $144.82. The company has a current ratio of 1.06, a quick ratio of 1.06 and a debt-to-equity ratio of 0.31. Icon Plc has a 1-year low of $66.57 and a 1-year high of $211.00. The stock has a market cap of $9.40 billion, a P/E ratio of 15.75, a P/E/G ratio of 3.04 and a beta of 1.23.

Analyst Upgrades and Downgrades

ICLR has been the subject of a number of recent research reports. TD Cowen upgraded shares of Icon from a “hold” rating to a “buy” rating and decreased their price target for the company from $183.00 to $120.00 in a research note on Wednesday, February 18th. Robert W. Baird set a $119.00 target price on shares of Icon in a research note on Friday, February 13th. Leerink Partners set a $125.00 target price on shares of Icon in a research note on Monday, May 4th. Barclays reduced their target price on shares of Icon from $200.00 to $120.00 and set an “equal weight” rating for the company in a research note on Monday, March 9th. Finally, Citigroup reduced their target price on shares of Icon from $200.00 to $120.00 and set a “neutral” rating for the company in a research note on Wednesday, March 11th. Seven equities research analysts have rated the stock with a Buy rating, five have given a Hold rating and three have given a Sell rating to the company. Based on data from MarketBeat.com, the stock has an average rating of “Hold” and an average price target of $149.38.

Icon Company Profile

Icon plc (NASDAQ: ICLR) is a global provider of outsourced drug development and clinical research services to the pharmaceutical, biotechnology and medical device industries. The company partners with clients at all stages of the product life cycle, offering expertise in protocol design, trial execution and regulatory compliance across a broad range of therapeutic areas.

Icon’s service portfolio encompasses clinical trial management, data management and biostatistics, medical imaging, pharmacovigilance and safety monitoring, laboratory sciences and specialized analytical solutions.